{"nct_id":"NCT06682988","title":"A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2025-05-28","start_date_type":"ACTUAL","primary_completion_date":"2028-03","primary_completion_date_type":"ESTIMATED","completion_date":"2028-03","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["ABBV"]}